Cyclin Dependent Kinase 2 - Pipeline Review, H1 2020
Cyclin Dependent Kinase 2 - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020'; Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) – Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).
The report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020' outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Ear Nose Throat Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Coronavirus Disease 2019 (COVID-19), Inflammation, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020'; Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) – Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).
The report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020' outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Ear Nose Throat Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Coronavirus Disease 2019 (COVID-19), Inflammation, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadraciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadraciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Pipeline by Apollo Therapeutics LLC, H1 2020
Pipeline by Astex Pharmaceuticals Inc, H1 2020
Pipeline by Cyclacel Pharmaceuticals Inc, H1 2020
Pipeline by G1 Therapeutics Inc, H1 2020
Pipeline by Neosome Life Sciences LLC, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Prous Institute for Biomedical Research SA, H1 2020
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H1 2020
Pipeline by Tiziana Life Sciences Plc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Pipeline by Apollo Therapeutics LLC, H1 2020
Pipeline by Astex Pharmaceuticals Inc, H1 2020
Pipeline by Cyclacel Pharmaceuticals Inc, H1 2020
Pipeline by G1 Therapeutics Inc, H1 2020
Pipeline by Neosome Life Sciences LLC, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Prous Institute for Biomedical Research SA, H1 2020
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H1 2020
Pipeline by Tiziana Life Sciences Plc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc
